Streamlining MEDITECH Ubrelvy Prior Authorization Workflows

Klivira accelerates MEDITECH Ubrelvy prior authorization by automating data extraction and submission, reducing manual effort for high-volume oral CGRP inhibitor requests.

Navigating prior authorizations for high-volume medications like Ubrelvy within the MEDITECH ecosystem presents unique challenges for revenue cycle directors and PA coordinators. The variability across MEDITECH product lines—from Expanse to legacy systems—demands a precise integration strategy to ensure efficient workflow and minimize denials.

Integrating Klivira with MEDITECH for Ubrelvy PA

Klivira connects directly with MEDITECH environments, leveraging available integration surfaces to automate the prior authorization process for Ubrelvy. For MEDITECH Expanse customers, this often includes FHIR R4 APIs and SMART App Launch capabilities to pull necessary clinical data and patient context directly from the EMR. For legacy MEDITECH product lines (Magic, C/S, 6.x), integration may utilize established HL7 v2 interfaces, ensuring broad compatibility across your health system's footprint.

Ubrelvy PA Flow within MEDITECH Order Entry

When a clinician places an order for Ubrelvy in MEDITECH, Klivira's integration can detect this trigger. For Expanse users, this workflow can be initiated via a SMART-launchable app directly from the patient chart or orders activity. The system automatically identifies the need for prior authorization based on payer rules and initiates the data collection process, often surfacing PA-related communications within MEDITECH's messaging workflows or surveillance worklists for clinician action.

Navigating Pharmacy vs. Medical Benefit for Oral CGRP Inhibitors

Oral CGRP inhibitors like Ubrelvy are typically covered under the pharmacy benefit, requiring ePA submission via NCPDP SCRIPT standards. Klivira's platform is equipped to handle these submissions, routing requests to the appropriate Pharmacy Benefit Managers (PBMs). While Ubrelvy itself is a pharmacy benefit drug, Klivira's comprehensive solution is designed to manage the broader spectrum of prior authorizations, including those that may fall under medical benefit for other CGRP inhibitors or related migraine therapies, ensuring all necessary channels are covered.

Automated Documentation Retrieval for Ubrelvy PA

A critical component of Ubrelvy prior authorization is robust clinical documentation. Klivira automatically extracts relevant information from MEDITECH's documentation modules, patient summary screens, and problem lists. This includes diagnosis codes, previous treatment failures, and other clinical notes required by payers to approve Ubrelvy, significantly reducing the manual effort of compiling PA packets.

Key Data Points Klivira Pulls from MEDITECH for Ubrelvy PA

Patient demographics and insurance information from ADT feeds or FHIR resources.
Diagnosis codes (ICD-10) and problem list entries related to migraine.
Medication history, including previous acute migraine treatments and failures.
Provider notes and clinical documentation supporting medical necessity.
Order details for Ubrelvy, including dosage and frequency.

Optimizing Specialty Pharmacy Routing and ePA Submission

For medications like Ubrelvy that often involve specialty pharmacies, Klivira streamlines the ePA submission process. Our platform connects directly with payer portals and utilizes X12 278 transactions or NCPDP SCRIPT for pharmacy benefit drugs, ensuring that prior authorization requests are submitted through the most efficient digital channels. This integration minimizes delays and supports timely medication access for patients.

Frequently asked questions

How does Klivira integrate with MEDITECH for Ubrelvy prior authorizations?

Klivira integrates with MEDITECH using available APIs, including FHIR R4 and SMART App Launch for Expanse, and HL7 v2 interfaces for legacy product lines. This allows us to pull patient demographics, clinical documentation, and order details directly from the EMR to automate the Ubrelvy prior authorization submission process.

What documentation does Klivira extract from MEDITECH for Ubrelvy PA?

Klivira extracts all necessary clinical documentation for Ubrelvy prior authorizations, including diagnosis codes, problem lists, medication history, and provider notes. This data, found in MEDITECH's documentation modules and patient summary, is automatically compiled to meet payer-specific requirements and support medical necessity.

Does Klivira support ePA for Ubrelvy through MEDITECH?

Yes, Klivira supports electronic prior authorization (ePA) for Ubrelvy. Our platform integrates with payer portals and utilizes NCPDP SCRIPT for pharmacy benefit submissions, which Ubrelvy typically falls under. This ensures efficient, digital submission of PA requests directly from your MEDITECH workflow.

How does Klivira handle the pharmacy vs. medical benefit split for Ubrelvy and similar drugs?

While Ubrelvy is primarily a pharmacy benefit drug, Klivira's system is designed to manage prior authorizations across both pharmacy and medical benefits. We route Ubrelvy requests via NCPDP SCRIPT to PBMs and can handle X12 278 submissions for medical benefit drugs or services, providing a comprehensive solution for complex medication classes.

What MEDITECH product lines are supported for Ubrelvy PA automation?

Klivira supports a range of MEDITECH product lines, with specific integration methods tailored to each. This includes modern Expanse deployments leveraging FHIR and SMART on FHIR, as well as legacy systems like Magic, C/S, and 6.x through established HL7 v2 interfaces. Our approach accounts for the product-line variability common across MEDITECH environments.